Grace Therapeutics FY2026 net loss $7.8M; FDA CRL for GTx-104; Type A meeting set

Grace Therapeutics, Inc.

Net loss of $7.8M ($0.47 loss per share) for FY2026, improved from $9.6M loss in FY2025.
Cash and equivalents $17.0M at March 31, 2026; expected to fund operations at least 12 months.
FDA issued Complete Response Letter for GTx-104 NDA in April 2026; no clinical deficiencies cited; Type A meeting scheduled.
Phase 3 STRIVE-ON trial met primary endpoint; 19% reduction in clinically significant hypotension vs oral nimodipine.
New U.S. patent (No. 12,414,943) for IV dosing regimen extends GTx-104 IP protection to 2043.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Grace Therapeutics, Inc. reported the fiscal year ended March 31, 2026 results: net income net loss of $7.8 million, EPS $0.47 loss per share.

Period: the fiscal year ended March 31, 2026
Net income: net loss of $7.8 million
EPS: $0.47 loss per share
Result: reported results

Exact text from the filing

The Company reported a net loss of $7.8 million, or $0.47 loss per share for the fiscal year ended March 31, 2026

View on SEC.gov

309 earnings releases filed in the last 30 days. Browse all earnings releases →

Grace Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-26-025667

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.